THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience

por Baum, Richard P., Kulkarni, Harshad R.
Publicado 2012

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy

por von Eyben, Finn Edler, Kulkarni, Harshad R., Baum, Richard P.
Publicado 2020

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with (177)Lu-PSMA and Combined (225)Ac- and (177)Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A S...

por Langbein, Thomas, Kulkarni, Harshad R., Schuchardt, Christiane, Mueller, Dirk, Volk, Gerd Fabian, Baum, Richard P.
Publicado 2022

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for (177)Lu-Labeled PSMA-Targeting Peptides

por Kletting, Peter, Schuchardt, Christiane, Kulkarni, Harshad R., Shahinfar, Mostafa, Singh, Aviral, Glatting, Gerhard, Baum, Richard P., Beer, Ambros J.
Publicado 2016

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

por von Eyben, Finn Edler, Singh, Aviral, Zhang, Jingjing, Nipsch, Karin, Meyrick, Danielle, Lenzo, Nat, Kairemo, Kalevi, Joensuu, Timo, Virgolini, Irene, Soydal, Cigdem, Kulkarni, Harshad R., Baum, Richard Paul
Publicado 2019

Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms

por Baum, Richard P., Kulkarni, Harshad R., Singh, Aviral, Kaemmerer, Daniel, Mueller, Dirk, Prasad, Vikas, Hommann, Merten, Robiller, Franz C., Niepsch, Karin, Franz, Holger, Jochems, Arthur, Lambin, Philippe, Hörsch, Dieter
Publicado 2018

Preclinical investigations and first-in-human application of $^{152}$Tb-PSMA-617 for PET/CT imaging of prostate cancer

por Müller, Cristina, Singh, Aviral, Umbricht, Christoph A, Kulkarni, Harshad R, Johnston, Karl, Benešová, Martina, Senftleben, Stefan, Müller, Dirk, Vermeulen, Christiaan, Schibli, Roger, Köster, Ulli, van der Meulen, Nicholas P, Baum, Richard P
Publicado 2019

Preclinical investigations and first-in-human application of (152)Tb-PSMA-617 for PET/CT imaging of prostate cancer

por Müller, Cristina, Singh, Aviral, Umbricht, Christoph A., Kulkarni, Harshad R., Johnston, Karl, Benešová, Martina, Senftleben, Stefan, Müller, Dirk, Vermeulen, Christiaan, Schibli, Roger, Köster, Ulli, van der Meulen, Nicholas P., Baum, Richard P.
Publicado 2019

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results

por Baum, Richard P., Schuchardt, Christiane, Singh, Aviral, Chantadisai, Maythinee, Robiller, Franz C., Zhang, Jingjing, Mueller, Dirk, Eismant, Alexander, Almaguel, Frankis, Zboralski, Dirk, Osterkamp, Frank, Hoehne, Aileen, Reineke, Ulrich, Smerling, Christiane, Kulkarni, Harshad R.
Publicado 2022

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with $^152$Tb-DOTATOC

por Baum, Richard P, Singh, Aviral, Benešová, Martina, Vermeulen, Christiaan, Gnesin, Silvano, Köster, Ulli, Johnston, Karl, Müller, Dirk, Senftleben, Stefan, Kulkarni, Harshad R, Türler, Andreas, Schibli, Roger, Prior, John O, van der Meulen, Nicholas P, Müller, Cristina
Publicado 2017

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study...

por Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kulkarni, Harshad R, Zhang, Jingjing, Gerke, Carolin, Fimmers, Rolf, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Maffey-Steffan, Johanna, Sathekge, Mike, Kabasakal, Levent, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene
Publicado 2020